ROS1 Gene Fusion Characteristics and Therapeutic Evolution

Dr. Wistuba provides detailed information about ROS1 gene fusions, discovered in the 1980s with over 30 to 40 fusion partners identified that constitutively activate ROS1 in cells, leading to malignant properties. The most frequent partner represents 40% of cases (CD74), with other partners including EZR, SLC34A2, and others comprising approximately 80% of cases collectively. The remaining cases involve rare fusion partners, highlighting the importance of RNA testing to identify new or rare partners not captured by DNA-based approaches.

ROS1 fusions occur in approximately 1% to 2% of patients with NSCLC, with enrichment in younger patients and those with limited tobacco history, though these alterations appear across all demographics, supporting universal rather than demographic-guided testing approaches. The data generally shows mutual exclusivity with other common genomic abnormalities in never-smokers, such as EGFR and ALK, though some studies indicate frequency increases to approximately 4% in younger never-smoker populations when these other drivers are absent.

Dr. Rodriguez reviews the therapeutic evolution in ROS1-positive NSCLC, describing progression from first-generation drugs (crizotinib and entrectinib) that achieved decent responses over 70% but lost efficacy due to resistance mutations and limited brain activity. Second-generation agents like repotrectinib demonstrated improved efficacy with 79% response rates and median PFS around 35 months, designed specifically for brain activity and durable responses. The newest agent, taletrectinib, shows impressive 80% response rates in both treatment-naive and previously treated patients with durable responses exceeding 44 months.

Dr. Leal discusses drug design evolution toward greater ROS1 selectivity, avoiding TRKB effects that caused problematic neurologic side effects. Although repotrectinib shows high responses and prolonged PFS, TRKB-related CNS side effects can be problematic in clinical practice. Newer drugs like taletrectinib demonstrate similar high response and intracranial response rates with the longest reported PFS over 45 months, but with improved tolerability due to ROS1 selectivity reducing TRKB side effects, though presenting different toxicity profiles including gastrointestinal effects and AST/ALT increases, mostly grade 1 with low treatment discontinuation rates.